RLAY Relay Therapeutics Inc

Price (delayed)

$19.87

Market cap

$2.16B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.56

Enterprise value

$2.08B

Relay Therapeutics, Inc. operates as a biotechnology company. The Company develops durgs for the treatment of cancer. Relay Therapeutics serves customers in the United States.

Highlights
The debt has contracted by 7% YoY and by 2% from the previous quarter
The EPS has dropped by 144% year-on-year but it has increased by 35% since the previous quarter
Relay Therapeutics's net income has increased by 30% QoQ but it has decreased by 13% YoY
Relay Therapeutics's revenue has plunged by 98% YoY and by 19% from the previous quarter
RLAY's gross profit has dropped by 98% year-on-year and by 19% since the previous quarter

Key stats

What are the main financial stats of RLAY
Market
Shares outstanding
108.9M
Market cap
$2.16B
Enterprise value
$2.08B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.77
Price to sales (P/S)
1,070.28
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1,029.01
Earnings
Revenue
$2.02M
EBIT
-$267.12M
EBITDA
-$263.15M
Free cash flow
-$206.44M
Per share
EPS
-$2.56
Free cash flow per share
-$1.9
Book value per share
$7.18
Revenue per share
$0.02
TBVPS
$8.17
Balance sheet
Total assets
$889.42M
Total liabilities
$109.78M
Debt
$22.02M
Equity
$779.64M
Working capital
$811.89M
Liquidity
Debt to equity
0.03
Current ratio
19.49
Quick ratio
19.15
Net debt/EBITDA
0.34
Margins
EBITDA margin
-13,046.4%
Gross margin
100%
Net margin
-13,243.6%
Operating margin
-13,426.1%
Efficiency
Return on assets
-30.4%
Return on equity
-34.6%
Return on invested capital
-39.3%
Return on capital employed
-31.6%
Return on sales
-13,243.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

RLAY stock price

How has the Relay Therapeutics stock price performed over time
Intraday
0.71%
1 week
9.96%
1 month
-10.94%
1 year
-39.6%
YTD
-35.3%
QTD
18.63%

Financial performance

How have Relay Therapeutics's revenue and profit performed over time
Revenue
$2.02M
Gross profit
$2.02M
Operating income
-$270.8M
Net income
-$267.12M
Gross margin
100%
Net margin
-13,243.6%
Relay Therapeutics's revenue has plunged by 98% YoY and by 19% from the previous quarter
RLAY's gross profit has dropped by 98% year-on-year and by 19% since the previous quarter
Relay Therapeutics's net income has increased by 30% QoQ but it has decreased by 13% YoY
RLAY's operating income is up by 30% since the previous quarter but it is down by 14% year-on-year

Growth

What is Relay Therapeutics's growth rate over time

Valuation

What is Relay Therapeutics stock price valuation
P/E
N/A
P/B
2.77
P/S
1,070.28
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1,029.01
The EPS has dropped by 144% year-on-year but it has increased by 35% since the previous quarter
The P/B is 28% lower than the last 4 quarters average of 3.8
The equity is up by 26% year-on-year but it has declined by 7% since the previous quarter
Relay Therapeutics's revenue has plunged by 98% YoY and by 19% from the previous quarter
The stock's price to sales (P/S) is 33% more than its last 4 quarters average of 799.9

Efficiency

How efficient is Relay Therapeutics business performance
The ROA is up by 44% YoY and by 34% QoQ
The company's return on equity rose by 41% YoY and by 34% QoQ
The return on invested capital has increased by 38% since the previous quarter and by 37% year-on-year
The return on sales has increased by 14% since the previous quarter

Dividends

What is RLAY's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for RLAY.

Financial health

How did Relay Therapeutics financials performed over time
RLAY's quick ratio is down by 28% year-on-year and by 11% since the previous quarter
RLAY's current ratio is down by 27% year-on-year and by 11% since the previous quarter
The debt is 97% less than the equity
The equity is up by 26% year-on-year but it has declined by 7% since the previous quarter
Relay Therapeutics's debt to equity has decreased by 25% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.